Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.71 |
| ▸ | PDE4A | P27815 | 12/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650057 | 0.86 | PDE4A (0.53) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2518447 | 0.84 | PDE4D (0.66) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL6571713 | 0.83 | PDE4B (0.59) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL18095182 | 0.83 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2887750 | 0.83 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL30084829 | 0.83 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29349467 | 0.83 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL19158 | 0.83 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2456573 | 0.82 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL5796349 | 0.82 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-02-28 | — | — | US | claimed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | claimed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-6528527-B2 | N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or the pyridyl-N-oxide thereof | MERCK & CO., INC. | 2003-03-04 | — | — | US | claimed |
| WO-2002038155-A1 | METHOD OF TREATMENT WITH A COMBINATION OF A PDE4 INHIBITOR AND A LEUKOTRIENE ANTAGONIST | MERCK & CO., INC. (US) | 2002-05-16 | — | — | WO | claimed |
| US-20020055520-A1 | Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist | MERCK SHARP & DOHME CORP. | 2002-05-09 | — | — | US | claimed |
| WO-2023110673-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2023-06-22 | — | — | WO | disclosed |
| WO-2012168907-A1 | PHARMACEUTICAL COMPOSITION COMPRISING REVAMILAST AND MONTELUKAST OR ZAFIRLUKAST | GLENMARK PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20090209599-A1 | Eye drop containing roflumilast | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209599-A1 | Eye drop containing roflumilast | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090186896-A1 | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders | BAYER HEALTHCARE AG (DE) | 2009-07-23 | — | — | US | disclosed |
| EP-1889620-A1 | EYE DROP CONTAINING ROFLUMILAST | Santen Pharmaceutical Co., Ltd (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6528527-B2 | N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or the pyridyl-N-oxide thereof | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-6528527-B2 | N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or the pyridyl-N-oxide thereof | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| WO-2002038155-A1 | METHOD OF TREATMENT WITH A COMBINATION OF A PDE4 INHIBITOR AND A LEUKOTRIENE ANTAGONIST | MERCK & CO., INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038155-A1 | METHOD OF TREATMENT WITH A COMBINATION OF A PDE4 INHIBITOR AND A LEUKOTRIENE ANTAGONIST | MERCK & CO., INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20020055520-A1 | Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist | MERCK SHARP & DOHME CORP. | 2002-05-09 | — | — | US | disclosed |
| US-20020055520-A1 | Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist | MERCK SHARP & DOHME CORP. | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PPARD, PPARG, PPARA | PDE4B 676/4885PDE4D 753/4885PDE4A 492/4885 |
| US-20020055520-A1 | Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist | PDE4A, PDE4B, LTA4H | PDE4B 2/4885PDE4D 8/4885PDE4A 1/4885 |
| US-20090209599-A1 | Eye drop containing roflumilast | PDE6A, PDE6D, PLAT | PDE4B 71/4885PDE4D 53/4885PDE4A 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.